Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NEULAND LABS vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NEULAND LABS   MYLAN
EQUITY SHARE DATA
    NEULAND LABS
Mar-23
MYLAN
Dec-18
NEULAND LABS/
MYLAN
5-Yr Chart
Click to enlarge
High Rs2,0043,967-   
Low Rs9662,184-   
Sales per share (Unadj.) Rs928.41,825.4-  
Earnings per share (Unadj.) Rs127.449.6-  
Cash flow per share (Unadj.) Rs168.6391.3-  
Dividends per share (Unadj.) Rs10.000-  
Avg Dividend yield %0.70-  
Book value per share (Unadj.) Rs774.81,974.7-  
Shares outstanding (eoy) m12.83514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x1.61.7 94.9%   
Avg P/E ratio x11.762.0 18.8%  
P/CF ratio (eoy) x8.87.9 112.1%  
Price / Book Value ratio x1.91.6 123.1%  
Dividend payout %7.80-   
Avg Mkt Cap Rs m19,0521,582,214 1.2%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m2,0180-   
Avg. sales/employee Rs Th026,833.1-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0728.6-  
INCOME DATA
Net Sales Rs m11,912939,158 1.3%  
Other income Rs m970-   
Total revenues Rs m12,009939,158 1.3%   
Gross profit Rs m2,718243,019 1.1%  
Depreciation Rs m528175,847 0.3%   
Interest Rs m13145,170 0.3%   
Profit before tax Rs m2,15722,002 9.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m522-3,500 -14.9%   
Profit after tax Rs m1,63525,502 6.4%  
Gross profit margin %22.825.9 88.2%  
Effective tax rate %24.2-15.9 -152.2%   
Net profit margin %13.72.7 505.5%  
BALANCE SHEET DATA
Current assets Rs m7,609524,425 1.5%   
Current liabilities Rs m4,390382,364 1.1%   
Net working cap to sales %27.015.1 178.7%  
Current ratio x1.71.4 126.4%  
Inventory Days Days684 7.6%  
Debtors Days Days1,10993 1,187.9%  
Net fixed assets Rs m8,189182,181 4.5%   
Share capital Rs m129500 25.8%   
"Free" reserves Rs m9,8120-   
Net worth Rs m9,9411,015,998 1.0%   
Long term debt Rs m7421,096,588 0.1%   
Total assets Rs m15,7982,725,301 0.6%  
Interest coverage x17.51.5 1,177.5%   
Debt to equity ratio x0.11.1 6.9%  
Sales to assets ratio x0.80.3 218.8%   
Return on assets %11.22.6 431.0%  
Return on equity %16.42.5 655.3%  
Return on capital %21.43.2 673.6%  
Exports to sales %73.50-   
Imports to sales %15.10-   
Net fx Rs m6,9460-   
CASH FLOW
From Operations Rs m2,372195,157 1.2%  
From Investments Rs m-615-100,875 0.6%  
From Financial Activity Rs m-1,358-90,916 1.5%  
Net Cashflow Rs m4031,617 24.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.34 Rs / USD

Compare NEULAND LABS With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare NEULAND LABS With: S.S.ORGANICS  PARNAX LAB  KABRA DRUGS  CHANDRA BHAGAT PHARMA  SANOFI INDIA  



Today's Market

Sensex Today Ends 487 Points Higher | Metal Stocks Shine | SBI & Axis Bank Zoom 5% Sensex Today Ends 487 Points Higher | Metal Stocks Shine | SBI & Axis Bank Zoom 5%(Closing)

After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.